Designer Probiotics for the treatment of intestinal infection and inflammation

用于治疗肠道感染和炎症的设计师益生菌

基本信息

  • 批准号:
    9769017
  • 负责人:
  • 金额:
    $ 73.51万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-09-23 至 2021-08-31
  • 项目状态:
    已结题

项目摘要

Project Summary New drug delivery platforms are vitally needed for the targeted delivery of high-specificity therapeutics to sites of disease in order to maximize therapeutic efficacy while limiting off-target side effects. The majority of efforts currently underway for the development of such targeted drug delivery systems are focused on the development of synthetic nanoparticles, materials which are costly to produce, store, and distribute. Here, we propose to develop cost-effective, self-replicating and flexible, programmable designer probiotics for the targeted delivery of therapeutics directly to sites of disease. We propose to utilize a synthetic biology approach to genetically engineer a widely and safely administered probiotic, Escherichia coli Nissle 1917, to express a nanomachine that can secrete therapeutic payloads into the intestinal milieu. These designer bacteria will be equipped with a type 3 secretion system modified to secrete proteins into the intestinal lumen rather than their innate target, the cytosol of mammalian cells. As proof of concept and towards the development of these designer probiotics as therapeutics, we will engineer these designer probiotics to secrete a new class of well- documented therapeutic biomolecules of exquisite specificity, single domain antibodies, also referred to as VHH. We will focus on the delivery of VHH multimers that exhibit profound neutralizing activity, VHH-based neutralizing agents (VNAs), which inhibit the activity of essential bacterial toxins or proinflammatory cytokines. Furthermore, we will investigate the potential of these strains as novel therapeutic paradigms for the treatment of both intestinal infections and inflammation disorders. Specifically, we will investigate the efficacy of these strains in the prevention of treatment of Clostridium difficile infections (CDI), hemolytic uremic syndrome (HUS) and inflammatory bowel disease (IBD). We appreciate that there might be some concern regarding the administration of genetically modified bacteria as therapeutics. However, as we enter the `era of the microbiome,' it seems extremely likely that such interventions are to become an integral component of the armamentarium utilized to treat infections and inflammatory disorders, particularly those rooted in the gastrointestinal tract, especially because of the high likelihood that such agents can overcome many issues associated with the wide-spread usages of antibiotics and systemic immunosuppressive agents. While efforts here are specifically devoted towards the development of these designer probiotics for the treatment of CDI, HUS, and IBD, once established as a therapeutic paradigm, this designer probiotic platform can be extended to treat a variety of intestinal based diseases. For example, the designer probiotics could be programmed to deliver a variety of protein-based therapeutic payloads, including cytokines, such as IL-10, that suppress intestinal inflammation or VNAs designed to target essential exposed virulence proteins of enteric bacterial pathogens, e.g., adhesins or essential components of virulence factor delivery systems.
项目摘要 新的药物递送平台对于将高特异性治疗剂靶向递送到位点是至关重要的 以最大限度地提高治疗效果,同时限制脱靶副作用。大多数努力 目前正在进行的这种靶向药物递送系统的开发集中在 合成纳米颗粒的开发,这些材料的生产、储存和分配成本很高。这里我们 建议开发具有成本效益,自我复制和灵活,可编程的设计师益生菌, 将治疗剂直接靶向递送至疾病部位。我们建议利用合成生物学方法 为了对广泛且安全施用的益生菌大肠杆菌Nissle 1917进行基因工程改造,以表达 纳米机器,可以分泌治疗有效载荷到肠道环境中。这些设计师细菌 配备有3型分泌系统,该系统被修改为将蛋白质分泌到肠腔中,而不是它们的 先天靶,哺乳动物细胞的胞质溶胶。作为概念的证明, 设计益生菌作为治疗,我们将设计这些设计益生菌分泌一类新的良好的, 有文献记载的具有精确特异性的治疗性生物分子,单结构域抗体,也被称为 VHH。我们将专注于VHH多聚体的递送,所述VHH多聚体表现出深刻的中和活性,基于VHH的中和活性,以及基于VHH的中和活性。 中和剂(VNA),其抑制必需的细菌毒素或促炎细胞因子的活性。 此外,我们还将研究这些菌株作为新的治疗范例的潜力。 肠道感染和炎症紊乱。具体来说,我们将研究这些药物的疗效。 用于预防和治疗艰难梭菌感染(CDI)、溶血性尿毒综合征(HUS) 和炎症性肠病(IBD)。我们理解,可能会有一些关注, 施用遗传修饰的细菌作为治疗剂。然而,当我们进入“时代”时, 微生物组,“似乎极有可能,这种干预措施将成为一个不可分割的组成部分, 用于治疗感染和炎症性疾病的医疗设备,特别是那些植根于 胃肠道,特别是因为这种药物很可能可以克服许多问题 与抗生素和全身免疫抑制剂的广泛使用有关。尽管工作 这里特别致力于开发这些设计的益生菌用于治疗CDI, HUS和IBD,一旦作为治疗范例建立,这种设计的益生菌平台可以扩展 治疗各种肠道疾病。例如,设计师益生菌可以被编程为 提供多种基于蛋白质的治疗有效载荷,包括抑制细胞因子(例如IL-10) 设计成靶向肠道细菌的必需暴露毒力蛋白的肠炎或VNA 病原体,例如,粘附素或毒力因子递送系统的必需组分。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Wendy S. Garrett其他文献

Immune recognition of microbial metabolites
微生物代谢物的免疫识别
  • DOI:
    10.1038/s41577-019-0252-2
  • 发表时间:
    2019-11-25
  • 期刊:
  • 影响因子:
    60.900
  • 作者:
    Wendy S. Garrett
  • 通讯作者:
    Wendy S. Garrett
Bacteria in cancer initiation, promotion and progression
癌症发生、促进和进展中的细菌
  • DOI:
    10.1038/s41568-023-00594-2
  • 发表时间:
    2023-07-03
  • 期刊:
  • 影响因子:
    66.800
  • 作者:
    Geniver El Tekle;Wendy S. Garrett
  • 通讯作者:
    Wendy S. Garrett
The metabolic sensor LKB1 regulates ILC3 homeostasis and mitochondrial function
代谢传感器 LKB1 调节 ILC3 稳态和线粒体功能
  • DOI:
    10.1016/j.celrep.2025.115456
  • 发表时间:
    2025-04-22
  • 期刊:
  • 影响因子:
    6.900
  • 作者:
    Diogo Fonseca-Pereira;Sena Bae;Slater L. Clay;Monia Michaud;Meghan H. MacDonald;Jonathan N. Glickman;Wendy S. Garrett
  • 通讯作者:
    Wendy S. Garrett
Engineered emEscherichia coli/em for the emin situ/em secretion of therapeutic nanobodies in the gut
用于肠道中治疗性纳米抗体原位分泌的工程化大肠杆菌
  • DOI:
    10.1016/j.chom.2023.03.007
  • 发表时间:
    2023-04-12
  • 期刊:
  • 影响因子:
    18.700
  • 作者:
    Jason P. Lynch;Coral González-Prieto;Analise Z. Reeves;Sena Bae;Urmila Powale;Neha P. Godbole;Jacqueline M. Tremblay;Florian I. Schmidt;Hidde L. Ploegh;Vikram Kansra;Jonathan N. Glickman;John M. Leong;Charles B. Shoemaker;Wendy S. Garrett;Cammie F. Lesser
  • 通讯作者:
    Cammie F. Lesser
Microbiota organization—a key to understanding CRC development
微生物群结构——理解 CRC 发展的关键

Wendy S. Garrett的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Wendy S. Garrett', 18)}}的其他基金

Designer Probiotics for the treatment of intestinal infection and inflammation
用于治疗肠道感染和炎症的设计师益生菌
  • 批准号:
    9356497
  • 财政年份:
    2016
  • 资助金额:
    $ 73.51万
  • 项目类别:
Designer Probiotics for the treatment of intestinal infection and inflammation
用于治疗肠道感染和炎症的设计师益生菌
  • 批准号:
    10004029
  • 财政年份:
    2016
  • 资助金额:
    $ 73.51万
  • 项目类别:
Gut microbiota and inflammatory monocytes in colorectal cancer
结直肠癌中的肠道微生物群和炎症单核细胞
  • 批准号:
    8816042
  • 财政年份:
    2011
  • 资助金额:
    $ 73.51万
  • 项目类别:
Colorectal carcinogenesis and Fusobacterium nucleatum: oncomicrobe, oncometabolites, and oncoimmunology
结直肠癌发生和具核梭杆菌:致癌微生物、致癌代谢物和肿瘤免疫学
  • 批准号:
    10665786
  • 财政年份:
    2011
  • 资助金额:
    $ 73.51万
  • 项目类别:
Colorectal carcinogenesis and Fusobacterium nucleatum: oncomicrobe, oncometabolites, and oncoimmunology
结直肠癌发生和具核梭杆菌:致癌微生物、致癌代谢物和肿瘤免疫学
  • 批准号:
    9977924
  • 财政年份:
    2011
  • 资助金额:
    $ 73.51万
  • 项目类别:
Colorectal carcinogenesis and Fusobacterium nucleatum: oncomicrobe, oncometabolites, and oncoimmunology
结直肠癌发生和具核梭杆菌:致癌微生物、致癌代谢物和肿瘤免疫学
  • 批准号:
    10207518
  • 财政年份:
    2011
  • 资助金额:
    $ 73.51万
  • 项目类别:
Gut microbiota and inflammatory monocytes in colorectal cancer
结直肠癌中的肠道微生物群和炎症单核细胞
  • 批准号:
    8444653
  • 财政年份:
    2011
  • 资助金额:
    $ 73.51万
  • 项目类别:
Gut microbiota and inflammatory monocytes in colorectal cancer
结直肠癌中的肠道微生物群和炎症单核细胞
  • 批准号:
    8607163
  • 财政年份:
    2011
  • 资助金额:
    $ 73.51万
  • 项目类别:
Colorectal carcinogenesis and Fusobacterium nucleatum: oncomicrobe, oncometabolites, and oncoimmunology
结直肠癌发生和具核梭杆菌:致癌微生物、致癌代谢物和肿瘤免疫学
  • 批准号:
    9307232
  • 财政年份:
    2011
  • 资助金额:
    $ 73.51万
  • 项目类别:
Gut microbiota and inflammatory monocytes in colorectal cancer
结直肠癌中的肠道微生物群和炎症单核细胞
  • 批准号:
    8021447
  • 财政年份:
    2011
  • 资助金额:
    $ 73.51万
  • 项目类别:

相似海外基金

The Importance and Function of Heme Degrading Enzymes during Anthrax Disease
炭疽病期间血红素降解酶的重要性和功能
  • 批准号:
    9323699
  • 财政年份:
    2017
  • 资助金额:
    $ 73.51万
  • 项目类别:
Nutrient Uptake during Anthrax Disease
炭疽病期间的营养吸收
  • 批准号:
    10053299
  • 财政年份:
    2012
  • 资助金额:
    $ 73.51万
  • 项目类别:
Nutrient Uptake during Anthrax Disease
炭疽病期间的营养吸收
  • 批准号:
    10296654
  • 财政年份:
    2012
  • 资助金额:
    $ 73.51万
  • 项目类别:
Edema Toxin Suppression of Immune Responses During Anthrax Disease
炭疽病期间水肿毒素抑制免疫反应
  • 批准号:
    7695606
  • 财政年份:
    2009
  • 资助金额:
    $ 73.51万
  • 项目类别:
Edema Toxin Suppression of Immune Responses During Anthrax Disease
炭疽病期间水肿毒素抑制免疫反应
  • 批准号:
    8716418
  • 财政年份:
  • 资助金额:
    $ 73.51万
  • 项目类别:
Edema Toxin Suppression of Immune Responses During Anthrax Disease
炭疽病期间水肿毒素抑制免疫反应
  • 批准号:
    8379006
  • 财政年份:
  • 资助金额:
    $ 73.51万
  • 项目类别:
Edema Toxin Suppression of Immune Responses During Anthrax Disease
炭疽病期间水肿毒素抑制免疫反应
  • 批准号:
    8137849
  • 财政年份:
  • 资助金额:
    $ 73.51万
  • 项目类别:
Edema Toxin Suppression of Immune Responses During Anthrax Disease
炭疽病期间水肿毒素抑制免疫反应
  • 批准号:
    8320309
  • 财政年份:
  • 资助金额:
    $ 73.51万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了